Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | BCHE | P06276 | 5/20 | 0.45 |
| ▸ | ACHE | P22303 | 5/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10843902 | 0.89 | KDM4E (0.45) | KDM4EHTTMEN1KMT2ATP53 | |
| SCHEMBL9874258 | 0.86 | KDM4E (0.48) | KDM4EHTTMEN1KMT2ABCHE | |
| SCHEMBL9874947 | 0.86 | KDM4E (0.51) | KDM4EHTTMEN1KMT2ABCHE | |
| SCHEMBL9875620 | 0.86 | KDM4E (0.46) | KDM4EHTTMEN1KMT2ABCHE | |
| SCHEMBL9875750 | 0.85 | KDM4E (0.49) | KDM4EHTTMEN1KMT2ATP53 | |
| SCHEMBL8984077 | 0.84 | KMT2A (0.67) | KDM4EHTTMEN1KMT2ABCHE | |
| SCHEMBL9875822 | 0.84 | KMT2A (0.57) | KDM4EHTTMEN1KMT2ATP53 | |
| SCHEMBL10846227 | 0.84 | KDM4E (0.51) | KDM4EHTTMEN1KMT2ABCHE | |
| SCHEMBL9876195 | 0.84 | CYP1A2 (0.51) | KDM4EHTTMEN1KMT2ATP53 | |
| Water SCHEMBL9876037 | 0.83 | CYP1A2 (0.50) | KDM4EHTTMEN1KMT2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4631286-A | MEMORY ENHANCERS | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1986-12-23 | — | — | US | claimed |
| EP-2681554-B1 | BLOOD COLLECTION DEVICE CONTAINING LYSOPHOSPHOLIPASE INHIBITOR | BECTON DICKINSON CO (US) | 2017-08-09 | — | — | EP | disclosed |
| US-9459187-B2 | Blood collection device containing lysophospholipase inhibitor | BECTON, DICKINSON AND COMPANY (US) | 2016-10-04 | — | — | US | disclosed |
| CN-104244902-A | Sample collection devices with blood stabilizing agents | BECTON DICKINSON CO | 2014-12-24 | — | — | CN | disclosed |
| US-20140030754-A1 | BLOOD COLLECTION DEVICE CONTAINING LYSOPHOSPHOLIPASE INHIBITOR | BECTON, DICKINSON AND COMPANY (US) | 2014-01-30 | — | — | US | disclosed |
| US-20130209985-A1 | SAMPLE COLLECTION DEVICES WITH BLOOD STABILIZING AGENTS | BECTON, DICKINSON AND COMPANY | 2013-08-15 | — | — | US | disclosed |
| EP-0179383-B1 | 9-AMINO-1,2,3,4-TETRAHYDROACRIDIN-1-OL AND RELATED COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1991-05-29 | — | — | EP | disclosed |
| US-4839364-A | ALZHEIMER*S DISEASE; CHOLINESTERASE INHIBITORS | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1989-06-13 | — | — | US | disclosed |
| US-4835275-A | Method of preparing 9-amino-1,2,3,4,-tetrahydroacridin-1-ones and related compounds | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1989-05-30 | — | — | US | disclosed |
| US-4754050-A | COGNITION ACTIVATORS | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1988-06-28 | — | — | US | disclosed |
| US-4695573-A | COGNITION ACTIVATORS | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1987-09-22 | — | — | US | disclosed |
| US-4631286-A | MEMORY ENHANCERS | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1986-12-23 | — | — | US | disclosed |
| EP-0179383-A2 | 9-Amino-1,2,3,4-tetrahydroacridin-1-ol and related compounds, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1986-04-30 | — | — | EP | disclosed |